Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Genomic Testing and ctDNA Add to Personalized Treatment Approach in Metastatic CRC
Benjamin Adam Weinberg, MD, discussed the expanding role of circulating tumor DNA in CRC and the various testing methods, the utilization of liquid biopsies, and the need for up-front genetic testing to identify molecular alterations.
Treatments for MCL Continue to Progress
October 14th 2022As research and treatment options for patients with mantle cell lymphoma continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step in the field.
Long-Term Treatment With Ibrutinib Is Possible in Newly Diagnosed CLL/SLL
October 13th 2022Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.
Ibrutinib Plus Venetoclax Improves Undetectable MRD Responses in Elderly, Unfit CLL
October 13th 2022Fixed-duration treatment with ibrutinib and venetoclax led to deeper and prolonged undetectable minimal residual disease responses vs chlorambucil and obinutuzumab in the frontline treatment of elderly or unfit patients with chronic lymphocytic leukemia, translating to fewer relapses in the first year following treatment cessation.
Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML
Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.
Increasingly Sensitive Genetic Testing Advances GI Cancer Diagnosis and Management
October 8th 2022John Lindsay Marshall, MD, discusses past, present, and future developments in molecular testing, as well as the unique offerings of tissue and blood tests and the ways in which these precise approaches will ultimately make cancer diagnosis and treatment more efficient and effective.
ASTX727/Venetoclax Combo Is Safe and Effective in First-Line and Relapsed/Refractory AML
October 5th 2022Oral decitabine plus cedazuridine added to oral venetoclax demonstrated promising overall response rates in patients with acute myeloid leukemia who received the combination as a first-line treatment or after relapsing on prior therapies.
Loncastuximab Tesirine/Rituximab Elicits Promising Anti-Tumor Activity in Relapsed/Refractory DLBCL
Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
Rusfertide Leads to Promising Phlebotomy Reduction in Polycythemia Vera
Treatment with rusfertide generated sustained hematocrit control at levels below 45% in patients with polycythemia vera, leading to a reduced need for repeated phlebotomy and eliminating this need in some patients, according to findings from 2 phase 2 clinical trials.
Ivosidenib/Azacitidine Combo Elicits Survival Benefit Over Placebo in IDH1-Mutated AML
September 29th 2022Ivosidenib plus azacitidine displayed favorable event-free survival, overall survival, and clinical responses compared with placebo plus azacitidine in patients with newly diagnosed, IDH1-mutated acute myeloid leukemia, according to findings from the phase 3 AGILE study.
Alpelisib Displays Clinical Benefit in Pediatric PIK3CA-Related Overgrowth Spectrum Disease
September 21st 2022Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.
The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.
PRMT5 Inhibitor Exhibits Efficacy and Tolerability in NHL, Advanced Solid Tumors
GSK3326595, a PRMT5 inhibitor, displayed modest efficacy and safety signals that were consistent with those that were previously reported with the agent among patients with advanced solid tumors.
HRQOL Outcomes in TNBC Are Not Negatively Affected by Pembrolizumab
September 12th 2022An analysis of patient-reported outcomes from the phase 2 KEYNOTE-522 trial demonstrated that pembrolizumab was not associated with effects on health-related quality of life in patients with triple-negative breast cancer.
ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL
Results from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and a tumor-specific biomarker for diffuse large B-cell lymphoma in China.
Orelabrutinib Plus R-CHOP Demonstrates Impressive ORR, PFS Rates in Non-GCB DLBCL
The combination of orelabrutinib and R-CHOP elicited a favorable overall response rate and progression-free response rate in patients with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (DLBCL) with extranodal disease.
Pembrolizumab/Olaparib Combo Fails to Improve rPFS, OS Vs Novel Hormonal Agents in mCRPC
September 12th 2022The combination of pembrolizumab and olaparib did not significantly improve radiographic progression-free survival and overall survival compared with novel hormonal agents in patients with molecularly unselected, previously treated metastatic castration-resistant prostate cancer.
Enfortumab Vedotin Plus Pembrolizumab Produces Encouraging Responses in Metastatic Urothelial Cancer
September 12th 2022The combination of enfortumab vedotin and pembrolizumab elicited a high overall response rate and a manageable safety profile in patients with locally advanced or metastatic urothelial cancer.
Tucatinib Plus Trastuzumab Elicits Responses in Crossover Cohort in HER2+ mCRC
September 12th 2022Tucatinib plus trastuzumab improved radiographic response rates in patients with metastatic HER2-positive colorectal cancer initially treated with tucatinib monotherapy who later crossed over to receive doublet therapy.
Trastuzumab Deruxtecan at Reduced Dose Maintains Efficacy in HER2-Mutated NSCLC
September 12th 2022The clinical benefit and tolerable safety profile of trastuzumab deruxtecan was maintained at 5.4 kg/mg vs 6.4 kg/mg in patients with HER2-mutated non–small cell lung cancer, confirming the benefit-risk ratio of the FDA-approved dose.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
